{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:49:44Z","timestamp":1782492584915,"version":"3.54.5"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"publisher","award":["A28724"],"award-info":[{"award-number":["A28724"]}],"id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"publisher","award":["RRCOER-Jun24\/100006"],"award-info":[{"award-number":["RRCOER-Jun24\/100006"]}],"id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C33589\/A28284"],"award-info":[{"award-number":["C33589\/A28284"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.prro.2026.04.015","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:12:03Z","timestamp":1778109123000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Adenocarcinoma: A Systematic Review and Meta-Analysis of Prospective Trials"],"prefix":"10.1016","author":[{"given":"K. Liang","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Gevaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Slotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0103-3591","authenticated-orcid":false,"given":"Sylvia S.W.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2026.04.015_bib0001","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Pancreatic Adenocarcinoma V.1.2025","year":"2025"},{"key":"10.1016\/j.prro.2026.04.015_bib0002","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","article-title":"Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection","volume":"270","author":"Gemenetzis","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.prro.2026.04.015_bib0003","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: A systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0004","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0005","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jnci\/80.10.751","article-title":"Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group","volume":"80","year":"1988","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.prro.2026.04.015_bib0006","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: The report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0007","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.clon.2012.04.006","article-title":"The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy","volume":"24","author":"Sahgal","year":"2012","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2026.04.015_bib0008","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijrobp.2009.09.042","article-title":"American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy","volume":"76","author":"Potters","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0009","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00066-020-01603-1","article-title":"Definition and quality requirements for stereotactic radiotherapy: Consensus statement from the DEGRO\/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery","volume":"196","author":"Guckenberger","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.prro.2026.04.015_bib0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation therapy for pancreatic cancer: Executive summary of an ASTRO clinical practice guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0011","unstructured":"US Department of Health and Human Services NIoH, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27."},{"key":"10.1016\/j.prro.2026.04.015_bib0012","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0013164409344534","article-title":"Weighting by inverse variance or by sample size in random-effects meta-analysis","volume":"70","author":"Mar\u00edn-Mart\u00ednez","year":"2010","journal-title":"Educ Psychol Meas"},{"key":"10.1016\/j.prro.2026.04.015_bib0013","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.prro.2026.04.015_bib0014","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome","volume":"155","author":"Teriaca","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0015","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.21037\/jgo-20-187","article-title":"A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses","volume":"11","author":"Liauw","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0016","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2026.04.015_bib0017","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.ijrobp.2021.02.008","article-title":"Phase I trial of stereotactic body radiation therapy dose escalation in pancreatic cancer","volume":"110","author":"Courtney","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0018","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0019","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S1470-2045(23)00478-3","article-title":"Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: An adaptive, randomised, double-blind, placebo-controlled, phase 1b\/2 trial","volume":"24","author":"Taniguchi","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1149961","article-title":"Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - A single center prospective cohort","volume":"13","author":"Doppenberg","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/cancers15010007","article-title":"Stereotactic MR-guided adaptive radiotherapy for pancreatic tumors: Updated results of the montpellier prospective registry study","volume":"15","author":"Bordeau","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2026.04.015_bib0022","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A Multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110347","article-title":"Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study","volume":"197","author":"Weisz Ejlsmark","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0024","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1245\/s10434-010-1019-y","article-title":"Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration","volume":"17","author":"Polistina","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0025","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1748-717X-8-148","article-title":"SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience","volume":"8","author":"Tozzi","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0026","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1533034616650778","article-title":"Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a Phase 2 study","volume":"16","author":"Comito","year":"2017","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.prro.2026.04.015_bib0027","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.prro.2017.10.001","article-title":"Results of a prospective phase 2 clinical trial of induction gemcitabine\/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma","volume":"8","author":"Quan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0028","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170563","article-title":"MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer","volume":"91","author":"Heerkens","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2026.04.015_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100818","article-title":"Analysis of the efficacy, safety and survival factors of stereotactic body radiation therapy in patients with recurrence of pancreatic cancer","volume":"13","author":"Li","year":"2020","journal-title":"Transl Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0030","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s12094-020-02287-w","article-title":"A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation in pancreatic cancer","volume":"22","author":"Chen-Zhao","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0031","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.clon.2020.06.019","article-title":"Hypofractionated stereotactic body radiation therapy with simultaneous integrated boost and simultaneous integrated protection in pancreatic ductal adenocarcinoma","volume":"33","author":"Simoni","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2026.04.015_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211045860","article-title":"Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma","volume":"13","author":"Bouchart","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0033","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.prro.2022.02.009","article-title":"Multiagent chemotherapy and stereotactic body radiation therapy in patients with unresectable pancreatic adenocarcinoma: A prospective nonrandomized controlled trial","volume":"12","author":"Hill","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0034","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijrobp.2023.03.036","article-title":"Phase 1 dose escalation study of SBRT using 3 fractions for locally advanced pancreatic cancer","volume":"117","author":"Reyngold","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0035","first-page":"15","article-title":"Combination of modified FOLFIRINOX with stereotactic body radiotherapy as an induction therapy for locally advanced pancreatic adenocarcinoma\u2014a prospective single-arm study","volume":"28","author":"Pi\u0105tek","year":"2024","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.prro.2026.04.015_bib0036","article-title":"Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study","volume":"45","author":"Salas","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0037","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.10.030","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer: A systematic review and pooled analysis of 19 trials","volume":"97","author":"Petrelli","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.906484","article-title":"Relationship of dose to vascular target volumes and local failure in pancreatic cancer patients undergoing neoadjuvant chemoradiation","volume":"12","author":"Nelson","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0039","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COC.0000000000000518","article-title":"Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer","volume":"42","author":"Kharofa","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0040","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/MPA.0000000000001602","article-title":"Patterns of failure after neoadjuvant stereotactic body radiation therapy or fractionated chemoradiation in resectable and borderline resectable pancreatic cancer","volume":"49","author":"Barrord","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.prro.2026.04.015_bib0041","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2024.10.026","article-title":"NRG oncology international consensus contouring Atlas on target volumes and dosing strategies for dose-escalated pancreatic cancer radiation therapy","volume":"121","author":"Sanford","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0042","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.ijrobp.2018.06.250","article-title":"Estimation of the Alpha-beta ratio for chemoradiation of locally advanced pancreatic cancer","volume":"102","author":"Prior","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0043","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0044","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2018.11.002","article-title":"Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma","volume":"132","author":"Lin","year":"2019","journal-title":"Radiother Oncol"},{"issue":"7 Suppl 3","key":"10.1016\/j.prro.2026.04.015_bib0046","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"suppl 1","key":"10.1016\/j.prro.2026.04.015_bib0047","doi-asserted-by":"crossref","first-page":"i53","DOI":"10.1093\/jrr\/rrw016","article-title":"Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer","volume":"57","author":"Crane","year":"2016","journal-title":"J Radiat Res"},{"key":"10.1016\/j.prro.2026.04.015_bib0048","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijrobp.2009.09.075","article-title":"A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer","volume":"78","author":"Murphy","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0049","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000322505","article-title":"Stereotactic body radiation therapy for gastrointestinal malignancies","volume":"43","author":"Minn","year":"2011","journal-title":"Front Radiat Ther Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/cancers10030075","article-title":"Stereotactic radiotherapy and particle therapy for pancreatic cancer","volume":"10","author":"Ng","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2026.04.015_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205917","article-title":"Variations of MRI-assessed peristaltic motions during radiation therapy","volume":"13","author":"Mostafaei","year":"2018","journal-title":"PLOS One"},{"key":"10.1016\/j.prro.2026.04.015_bib0052","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ijrobp.2009.02.003","article-title":"Characterization of pancreatic tumor motion using cine MRI: Surrogates for tumor position should be used with caution","volume":"74","author":"Feng","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0053","article-title":"Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for locally advanced pancreatic cancer: A promising approach","volume":"10","author":"Luterstein","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.prro.2026.04.015_bib0054","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13014-018-1000-7","article-title":"Optimization of treatment planning workflow and tumor coverage during daily adaptive magnetic resonance image guided radiation therapy (MR-IGRT) of pancreatic cancer","volume":"13","author":"Olberg","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13014-022-02021-6","article-title":"Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: Liver, lung, abdominal lymph nodes, pancreas and prostate","volume":"17","author":"Nierer","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0056","article-title":"Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online MR-guided adaptation","volume":"6","author":"Hassanzadeh","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0057","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.prro.2026.04.015_bib0058","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer","volume":"11","author":"Chuong","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0059","article-title":"Dosimetric predictors of acute and late gastrointestinal toxicities in stereotactic online adaptive magnetic resonance-guided radiotherapy (SMART) for locally advanced pancreatic adenocarcinoma","volume":"200","author":"D'Souza","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0060","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(22)00066-3","article-title":"Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: An open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Zhu","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0061","doi-asserted-by":"crossref","first-page":"6736","DOI":"10.1002\/cam4.4214","article-title":"Phase I study of dose-escalated stereotactic body radiation therapy for locally advanced pancreatic head cancers: Initial clinical results","volume":"10","author":"Qing","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.prro.2026.04.015_bib0062","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijrobp.2020.09.010","article-title":"A phase 1 dose escalation study of neoadjuvant SBRT plus elective nodal radiation with concurrent capecitabine for resectable pancreatic cancer","volume":"109","author":"Witt","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0063","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jmrs.313","article-title":"Application of stereotactic body radiotherapy in advanced pancreatic cancers in Australia","volume":"66","author":"Kim","year":"2019","journal-title":"J Med Radiat Sci"},{"key":"10.1016\/j.prro.2026.04.015_bib0064","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1748-717X-8-44","article-title":"Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: A pilot trial demonstrating safety","volume":"8","author":"Gurka","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109541","volume":"183","author":"van 't Land","year":"2023","journal-title":"Radiother Oncol"},{"issue":"16_suppl","key":"10.1016\/j.prro.2026.04.015_bib0066","doi-asserted-by":"crossref","first-page":"TPS4191","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4191","article-title":"Sequential treatment with gemcitabine\/nab-paclitaxel (GA) and FOLFIRINOX (FFX) followed by stereotactic MRI-guided adaptive radiation therapy (SMART) in patients with locally advanced pancreatic cancer (LAPC): GABRINOX-ART phase 2, multicenter trial","volume":"40","author":"Portales","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.04.015_bib0067","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijrobp.2019.02.047","article-title":"Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death","volume":"110","author":"Song","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2020.10.039","article-title":"High dose per fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An overview","volume":"110","author":"Grimm","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.04.015_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.866173","article-title":"Predictive biomarkers for a personalized approach in resectable pancreatic cancer","volume":"9","author":"Merz","year":"2022","journal-title":"Front Surg"},{"key":"10.1016\/j.prro.2026.04.015_bib0070","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026001402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026001402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:20:59Z","timestamp":1782490859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850026001402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":70,"alternative-id":["S1879850026001402"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2026.04.015","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Adenocarcinoma: A Systematic Review and Meta-Analysis of Prospective Trials","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2026.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}